A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With Relapsed/Refractory Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2018
At a glance
- Drugs AMG-119 (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; First in man
- Sponsors Amgen
- 05 Nov 2018 Planned End Date changed from 9 Sep 2020 to 30 Aug 2020.
- 05 Nov 2018 Planned primary completion date changed from 9 Sep 2020 to 30 Aug 2020.
- 26 Sep 2018 Trial design presented at the 19th World Conference on Lung Cancer